Ten years ago, Dr. Stephan Grupp, MD, PhD, led the first phase 1 trial of Penn-invented CAR-T (chimeric antigen receptor T-cell) cell therapy in partnership with Penn and Novartis for acute lymphoblastic leukemia (ALL) with 6-year-old patient Emily Whitehead at the Children’s Hospital of Philadelphia (CHOP).
Since that single CAR-T cell therapy treatment in 2012, Emily has remained free of her leukemia and in remission for more than 10 years.
Read more about CAR-T and Emily Whitehead’s story here.